Edition:
United States

BeiGene Regains Global Rights to Investigational Anti-PD-1 Antibody Tislelizumab


Monday, 17 Jun 2019 07:00am EDT 

June 17 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE REGAINS FULL GLOBAL RIGHTS TO ITS INVESTIGATIONAL ANTI-PD-1 ANTIBODY TISLELIZUMAB.BEIGENE LTD - ENTERED INTO A MUTUAL AGREEMENT WITH CELGENE CORPORATION TO TERMINATE PARTIES' GLOBAL COLLABORATION FOR TISLELIZUMAB.BEIGENE LTD - IN CONNECTION WITH TERMINATION, CELGENE HAS AGREED TO PAY $150 MILLION TO BEIGENE.BEIGENE LTD - BEIGENE EXPECTS TISLELIZUMAB TO RECEIVE ITS FIRST REGULATORY APPROVAL LATER THIS YEAR.. 

Company Quote

124.36
-0.04 -0.03%
4:00pm EDT